Looking at the trends in patents and in the new drugs working their way along the pipelines of the innovative pharmaceutical companies, it’s clear that biotechnology drugs are the future for the treatment of diseases around the world. It’s also clear that personalised medicine will become a reality for more and more people as biotechnology develops further and the performance of drugs improves.
If you don't have a login or your access has expired, you will need to purchase a subscription to gain access to this article, including all our online content.
For more information on individual annual subscriptions for full paid access and corporate subscription options please contact us.
To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.
For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk
7 September 2017 Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.
7 September 2017 Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.
7 September 2017 Biotechnology companies Bioverativ and Bicycle Therapeutics have entered into an agreement to develop and commercialise therapies for haemophilia and sickle cell disease.